Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• COVID-19 vaccine (recombinant protein, adjuvanted) or Nuvaxovid is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals aged 12 years and older.
• Eight studies were reviewed that centered around Nuvaxovid's safety and effectiveness compared with other COVID vaccines, considering various population types and subgroup considerations.
• The studies highlight heterologous vaccination schedules as effective with no significant difference in serious adverse events among different vaccines. This information can guide decisions regarding vaccination schedules.
• A study focusing on children worldwide indicates a high percentage of them are still susceptible to SARS-CoV-2 infection, emphasizing the need for improved vaccine coverage within this age group.
• The network meta-analysis from one study shows BNT162b2 offers the highest protection against symptomatic SARS-CoV-2 infection followed by mRNA1273, rAD26 & rAD5, NVX-COV2373, indicating varying levels of efficacy across different vaccines.
• Inactivated COVID-19 vaccines like Novavax are reported to have milder side effects and fewer life-threatening adverse events compared to other vaccine types according to their safety profile evaluation; this may be an important consideration for those who are concerned about potential side effects.